Intraocular pressure (IOP) is the only modifiable risk factor for glaucoma, and lowering of IOP remains the mainstay of glaucoma treatment. IOP is a dynamic biologic parameter, nevertheless, current glaucoma management usually relies on single IOP measurements during clinic hours. However, a majority of glaucoma patients have their high, including their highest, IOP levels outside clinic hours. These undetected IOPs may explain why certain patients have progressive disease despite treatment. The interest in continuous 24-hour IOP monitoring started over half a century ago, but only recent technologic advances have provided clinicians with a practical device for continuous IOP monitoring. In this article, we discuss innovative approaches with permanent and temporary devices for 24-hour IOP monitoring, such as a contact lens sensor. Despite being in their infancy, these devices may soon enable clinicians to use 24-hour IOP data to improve glaucoma management and reduce the glaucoma-related burden of disease.
Glaucoma is a progressive optic neuropathy, characterized by the loss of retinal ganglion cells and its axons ultimately leading to loss of vision and subsequent irreversible blindness. 1 Elevated intraocular pressure (IOP) is the only proven modifiable risk factor for the development and progression of glaucoma. [2] [3] [4] [5] Despite dedicated efforts to develop alternative therapies, reduction of IOP remains the current mainstay of glaucoma treatment.
One important limitation in current glaucoma management is that IOP is normally only measured during office hours, usually by Goldmann applanation tonometry (GAT). 6 Yet IOP varies throughout the circadian period. [7] [8] [9] [10] [11] In addition to the absolute IOP level, [12] [13] [14] [15] [16] IOP fluctuations, 2, 13, [17] [18] [19] [20] and in particular peak IOP levels have been identified as risk factors for progression of glaucoma. [21] [22] [23] The role of IOP fluctuations in glaucoma pathogenesis remains controversial. Several studies have hypothesized that IOP fluctuation is an independent risk factor for glaucoma progression. [24] [25] [26] [27] [28] In an experimental setting in non-human primates, mean and maximum IOP but not IOP variability were able to predict the rate of structural change. 29 The same investigators also reported that IOP fluctuates by up to 10 mmHg within hours and between consecutive days in non-human primates. 30 Given the dynamic behavior of IOP, it may be clinically insufficient to rely on isolated IOP measurements only, in particular in patients with progression of glaucoma. Even the modest goal of obtaining representative diurnal (versus circadian) IOP profiles, our current methods seem to be insufficient.
In one study, the likelihood of a single IOP measurement taken between 07:00-09:00 hours to reflect the daytime peak IOP was a mere 25 %. 33 Other studies reported that 20-25 % of glaucoma patients who reached target IOP during isolated office measurements exhibited IOPs above the target level when submitted to a daytime IOP curve assessment. 9, 24 Patients with progressive visual field loss are more likely to have IOP peaks. Among patients presenting with IOP peaks during self-tonometry, 75 % had progressive glaucomatous disease compared with the patients without IOP peaks out of which only 25 % progressed. 25 Compared with 24-hour IOP measurement curves, office hour IOP measurements did not correctly identify peak IOP in 80 % of patients with primary open angle glaucoma (POAG). 10 These studies attest to the weak predictive value of office hour IOP measurements for detecting peak circadian IOP.
In healthy and glaucomatous patients, IOP is higher than mean diurnal 40 In these studies, a lower than normal IOP reproducibility may in part be explained by the limited number of daytime IOP measurements.
Current treatment strategies for glaucoma are frequently based on setting a target IOP range at which the development of further glaucomatous damage is assumed be prevented or reduced to a minimum. 
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US OPHTHALMIC REVIEW is not affected. The pressure is exerted equally in all directions of the eye's external surface and is determined by the resistance to distension of the intraocular volume to these structures (e.g. cornea, sclera, etc.).
IOP changes are a consequence of volume changes of the eye contents and are partially determined by the resistance offered by the cornea and sclera to distension of the volume.
Calibration of the CLS output to mmHg is a challenge as simultaneous use of the CLS and tonometry on the same eye is not feasible. Therefore, simultaneous comparison between the CLS and tonometry is to be performed in the contralateral eye, despite the moderate relationship of IOP measurements between eyes. 53 A better approach would be to compare IOP monitoring with the CLS and an implantable device in the same eye. This will be the subject of future research.
Contact Lens Sensor Safety and Tolerability
A recent study evaluated the safety and tolerability of 24-hour IOP recording by using the CLS in patients with suspected glaucoma and with POAG. 34 All 40 patients, 21 suspected and 19 established glaucoma, with a mean age 55.5±15.7 years (60 % male) were exposed to the CLS wear for 24 hours on the same eye during two sessions (S1 and S2) seven days 
The contact lens sensor (CLS) was successfully fitted on the globe and cannulation of the posterior chamber was performed through a 26 G needle. The graph shows the rapid increase and subsequent stabilization of the CLS signal when the intraocular pressure (IOP) was raised in two 10 mmHg steps.
The acrophase occurred during the nocturnal sleep phase on two subsequent visits, one month apart.
Two other patients with established glaucoma (5.1 %) each had a severe AE (2.7 %) during both sessions-ocular hyperemia. The first clinical study used the CLS in 10 healthy subjects for 24 hours did not report any severe AEs. 54 Five severe AEs were reported, one in a healthy subject and four in patients with POAG, in a study designed to assess the safety of CLS exposure. 55 All device-related AEs resolved within 48 hours.
A total of 88 subjects across three trials, 29 healthy subjects, and 21
patients with suspected glaucoma and 38 with established glaucoma, reported tolerability by means of a visual analog scale equating to percentage comfort level to 24-hour wear of the CLS. 24, [54] [55] [56] The mean comfort level was good after 24-hour CLS wear (score 75 %). No apparent differences for the comfort level were observed across studies, for the different diagnostic groups, or the fact that 40 subjects were exposed to CLS wear twice one week apart. p<0.001). 34 Based on these data, the use of CLS is considered to be safe and well tolerated for the recording of the 24-hour IOP patterns.
Validation and Reproducibility of Intraocular Pressure Monitoring Patterns
The CLS has previously been validated ex vivo in enucleated porcine eyes with good agreement of the CLS output with manometry values. 50 For practical reasons, mostly related to obtaining a good fit of the sensor on the ocular surface, in vivo manometric studies in animal models and patients are more difficult. However, despite these difficulties, whenever a good fit is obtained, we find a close correlation of the CLS signal output and manometric measures. (see Figure 2) . 
Conclusion
The use of the CLS for the recording of the 24-hour IOP pattern is safe and well-tolerated in healthy subjects and glaucomatous patients. Despite its infancy and the current existence of barriers to the use and interpretation of data in a clinical setting, recent evidence shows that this technology provides reproducible and clinically useful results for the entire 24-hour period, including the previously inaccessible sleep period. In the near future, introduction of alternative technologies is expected into clinical practice. With these advances, there will be an enhanced understanding of the IOP pattern and this should substantially improve the management of glaucoma patients. n
